Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends That Matter for Breast Cancer Treatment

Posted by Matt Breese on Jan 25, 2018

Find me on:

new-blog-image-development.png

In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is a new treatment for breast cancer.

The FDA recently approved the use of Lynparza (olaparib tablets) to treat patients with metastasized breast cancer and whose tumors have a specific inherited genetic mutation. Lynparza becomes the first PARP inhibitor approved for breast cancer and the first drug for treatment of patients with a BRCA mutation. 

According to the National Cancer Institute at the National Institutes of Health, about 20% to 25% of patients with hereditary breast cancers and 5% to 10% of patients with any type of breast cancer have a BRCA gene mutation. 

Lynparza blocks an enzyme involved in repairing damaged DNA. By preventing DNA inside BRCA-mutated cancerous cells from being repaired, the drug could slow down or stop tumor growth. 

Patients may receive treatment with Lynparza after undergoing the FDA-approved genetic test BRACAnalysis CDx. 


Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.

Subscribe for Weekly Trends that Matter 

Topics: Industry Trends, Product Release